Table 1 Demographic and clinical characteristics at presentation of patients with primary FSGS (N = 8).
Variable | |
|---|---|
Sex - N (%) | |
Female | 3 (37.5%) |
Male | 5 (62.5%) |
Ethnicity - N (%) | |
Arab/Moslem | 6 (75%) |
Arab/Christian | 1 (12.5%) |
Jewish | 1 (12.5%) |
Primary histopathology - N (%) | |
FSGS | 4 (50%) |
MCD | 3 (37.5%) |
Unknown | 1 (12.5%) |
Age at presentation, years | |
Median | 6 |
Average (SD) | 7 (4.75) |
Primary steroid sensitivity - N (%) | |
Yes | 3 (37.5%) |
No | 5 (62.5%) |
Genetic testing - N (%) | |
Yes, negative results | 7 (87.5%) |
No | 1 (12.5%) |
Time to kidney failure, years | |
Median | 3 |
Average (SD) | 4.3 (4.2) |
Donor source - N (%) | |
Living related donor | 3 (37.5%) |
Deceased donor | 5 (62.5%) |
Preemptive PP - N (%) | |
Yes | 5 (62.5%) |
No | 3 (37.5%) |
Induction protocol - N (%) | |
Basiliximab + corticosteroids | 7 (87.5%) |
Thymoglobulin + corticosteroids | 1 (12.5%) |
Delayed Graft function - N (%) | |
Yes | 3 (37.5%) |
No | 5 (62.5%) |
Maintenance drug regimen - N (%) | |
MMF + Tacrolimus + steroids | 8 (100%) |
rFSGS - N (%) | |
Yes | 6 (75%) |
No | 2 (25%) |
Time to recurrence, days | |
Median | 2.5 |
Average (SD) | 12.5 (23) |
